make it possible

We invite you to participate in our financing round and become a shareholder of AbilityPharma

I want to invest

AbilityPharma is a biopharmaceutical company developing new first-in-class candidates to treat cancer. We are focused on autophagy as a new therapeutic strategy to induce cancer cell death. Based on this novel mechanism of action, we are generating a portfolio of new drugs targeting oncological unmet needs.

Media Center

22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020

Press Release

ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
22.10.2020

In the media

Ability logra financiación de la FDA y abre una ronda en Capital Cell + info
22.10.2020

In the media

Ability Pharma capta dos millones de dólares de la FDA para su ensayo clínico de páncreas + info
March

Events

BIO-Europe Spring. Paris (France) + info
February

Events

15th Biomarkers Series UK. Manchester (United Kingdom) - Marc Yeste, PhD: Pharmacodynamic biomarkers associated to ABTL0812, a phase 2 clinical stage pro-autophagy anticancer drug + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG